Alto Neuroscience’s (ANRO) Outperform Rating Reaffirmed at William Blair

Alto Neuroscience (NYSE:ANRO)‘s stock had its “outperform” rating reiterated by stock analysts at William Blair in a note issued to investors on Friday,RTT News reports.

Alto Neuroscience Price Performance

NYSE ANRO traded down $0.04 during trading on Friday, reaching $2.65. The company’s stock had a trading volume of 121,727 shares, compared to its average volume of 358,117. The company has a current ratio of 13.10, a quick ratio of 13.09 and a debt-to-equity ratio of 0.05. Alto Neuroscience has a twelve month low of $2.60 and a twelve month high of $18.35. The business’s fifty day moving average price is $3.67 and its 200-day moving average price is $6.22.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.09. On average, research analysts forecast that Alto Neuroscience will post -2.54 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Wells Fargo & Company MN boosted its holdings in Alto Neuroscience by 40.0% during the fourth quarter. Wells Fargo & Company MN now owns 10,989 shares of the company’s stock worth $46,000 after buying an additional 3,139 shares in the last quarter. Deutsche Bank AG lifted its holdings in shares of Alto Neuroscience by 31.3% in the fourth quarter. Deutsche Bank AG now owns 15,210 shares of the company’s stock valued at $64,000 after purchasing an additional 3,629 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Alto Neuroscience by 619.2% in the third quarter. BNP Paribas Financial Markets now owns 4,315 shares of the company’s stock valued at $49,000 after purchasing an additional 3,715 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Alto Neuroscience by 24.4% in the fourth quarter. Rhumbline Advisers now owns 25,556 shares of the company’s stock valued at $108,000 after purchasing an additional 5,008 shares in the last quarter. Finally, Philadelphia Financial Management of San Francisco LLC lifted its holdings in shares of Alto Neuroscience by 1.5% in the third quarter. Philadelphia Financial Management of San Francisco LLC now owns 449,952 shares of the company’s stock valued at $5,147,000 after purchasing an additional 6,663 shares in the last quarter.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.